“Organoid Therapeutics gives patients the opportunity to regain control of their health and the ability to return to daily life,” said Richard Simon, producer for the Advancements series.
JUPITER, Fla. (PRWEB)
May 07, 2020
Scheduled to broadcast in the fall of 2020, Advancements with Ted Danson will focus on innovations in artificial organ technologies for the treatment of endocrine disorders. Check local listings for more info.
This segment will take a look at Organoid Therapeutics, Inc. (Organoid Therapeutics) and will educate about the development of its organoid-based therapies to correct hormone deficiencies and cure diseases, such as diabetes, hypothyroidism, and infertility.
Viewers will learn about Organoid Therapeutics’ portfolio of patent-pending organ engineering and tissue repair technologies, which span multidisciplinary fields, including engineering, and advanced robotics for large scale manufacturing.
“We are extremely excited to share our technology and believe it has the potential to cure diseases such as diabetes, hypothyroidism, and infertility. Our commercial product will be off-the-shelf universally compatible organoids that will replace current therapies like daily insulin injections and daily medications. We currently have proof of concept for this technology and are finalizing a prototype for preclinical and clinical evaluation. We hope viewers take interest in our cause and follow our journey to market,” said Denver Faulk, PhD, CEO & Co-founder.
Patients with chronic conditions face a number of important barriers to adequate disease management, including lack of access to medication, overly complex treatment regimens with serious side effects, increased complication and mortality rates, and disproportionate financial strain. Organoid Therapeutics’ biopharmaceutical products offer patients with end-stage glandular organ disease an alternative to a lifetime of pharmacological therapy.
“Organoid Therapeutics gives patients the opportunity to regain control of their health and the ability to return to daily life,” said Richard Simon, producer for the Advancements series. “We are excited to explore the technology and share this information with the public.”
About Organoid Therapeutics:
Organoid Therapeutics is a Pittsburgh based biotech company with a mission of using advanced robotics to mass produce off-the-shelf, universally compatible functional organs to treat patients around the world suffering from organ failure. The company believes its functional human organs will cure endocrine disorders such as diabetes, thyroid disease, and infertility. Its focus is to develop artificial organ technologies to offer patients with end stage organ disease a curative alternative to continuous maintenance therapy.
In the future, Organoid Therapeutics plans to develop other organoids to address other glandular diseases such as hypothyroidism and infertility and to offer its revolutionary treatment as universally accessible by creating organoid banks and outpatient centers where diabetes, hypothyroidism, and other glandular organ deficiencies can be treated with minimally invasive implantation of the organoids.
For more information, visit: http://www.organoidtherapeutics.co.
About Advancements and DMG Productions:
The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.
Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.
For more information, please visit http://www.AdvancementsTV.com or call Richard Simon at 866-496-4065.
Share article on social media or email: